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Abstract
A single 6-min walk test (6MWT) can be used to identify children with dilated cardiomyopathy (DCM) with a high risk 
of death or heart transplantation. To determine if repeated 6MWT has added value in addition to a single 6MWT in pre-
dicting death or heart transplantation in children with DCM. Prospective multicenter cohort study including ambulatory 
DCM patients ≥ 6 years. A 6MWT was performed 1 to 4 times per year. The distance walked was expressed as percentage 
of predicted (6MWD%). We compared the temporal evolution of 6MWD% in patients with and without the study endpoint 
(SE: all-cause death or heart transplantation), using a linear mixed effects model. In 57 patients, we obtained a median of 4 
(IQR 2–6) 6MWTs per patient during a median of 3.0 years of observation (IQR 1.5–5.1). Fourteen patients reached a SE (3 
deaths, 11 heart transplantations). At any time during follow-up, the average estimate of 6MWD% was significantly lower 
in patients with a SE compared to patients without a SE. In both patients groups, 6MWD% remained constant over time. 
An absolute 1% lower 6MWD% was associated with an 11% higher risk (hazard) of the SE (HR 0.90, 95% CI 0.86–0.95 
p < 0.001). Children with DCM who died or underwent heart transplantation had systematically reduced 6MWD%. The 
performance of all patients was stable over time, so repeated measurement of 6MWT within this time frame had little added 
value over a single test.
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Introduction
The 6-min walk test (6MWT) is a safe, simple, and well-
accepted prognostic tool in adults with heart failure [1]. The 
test is used as an outcome measure in clinical trials, and 
short-term change in 6MWT is considered an indicator of 
prognosis as well [2–4].
In children, the 6MWT is also feasible and has been 
shown to be reproducible [5]. The distance walked in a 
6MWT can be expressed as a percentage of predicted, taken 
into account height, gender, and age (6MWD%) [6]. The 
6MWT has been successfully used to predict outcome in 
pediatric patients with pulmonary hypertension [7] and to 
evaluate therapy effects in patients with Duchenne muscular 
dystrophy [8] and pulmonary hypertension [9]. Previously, 
we showed that in children with dilated cardiomyopathy 
(DCM), a single 6MWD% below 63% identified patients 
with the highest risk of dying or heart transplantation (HTx) 
[10].
In this study, we report the results of repeated 6MWT in 
children with DCM. We studied the evolution of 6MWD% 
over time in relation to death or HTx. We aim to determine 
whether 6MWD% changes over time, and if so, if this change 
is associated with the risk of dying or HTx. We hypothesize 
that repeated measurement of 6MWT has added value over 
a single measurement in predicting these clinical outcomes.
Methods
Data were collected in a multicenter, prospective study 
design. In total, patients from eight tertiary cardiac centers 
were included, covering potentially the whole Dutch popu-
lation of children with DCM. Our research program started 
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in October 2010 and ended in July 2017. In this period, we 
enrolled children with a previous diagnosis of DCM until 
2010, relatively late after diagnosis, or with a new diag-
nosis from 2010 and onward, early after diagnosis. DCM 
was defined as the presence of impaired systolic function 
(fractional shortening (FS) ≤ 25%) and left ventricular (LV) 
dilation (LV end-diastolic dimension (LVEDD) >  + 2 Z 
score for body surface area). Patients with neuromuscular 
disease, cognitive impairment, or structural heart disease 
were excluded. The research program was organized in such 
a way that study visits coincided with routine outpatient 
clinic visits. In the first year after diagnosis, 6MWTs were 
obtained 1 to 4 times per year, and 1 to 2 times per year 
thereafter, dependent on the frequency of visits. This study 
was approved by the medical ethical committee of the Eras-
mus MC (MEC 2014–062) and performed in accordance 
with the declaration of Helsinki. All parents and children 
≥ 12 years gave their written informed consent.
All included patients were asked to perform 6MWTs 
as part of our follow-up study program, at the outpatient 
clinic in the participating centers. The 6MWT was con-
ducted according to the guidelines of the American Thoracic 
Society [11]. The local conditions at the outpatient clinics 
required adaptation of the walking track, as described previ-
ously [10]. In summary, patients were instructed to walk as 
far as possible on an 8-m track within a 6-min time frame. 
Patients were instructed and encouraged in a standardized 
manner. Running was not allowed, if necessary, patients 
could slow down or stop walking. After 6 min, the total 
amount of 16 m ‘laps’ was counted and the distance walked 
in a partially finished lap was added, which resulted in a total 
walking distance (6 MWD). If the patient stopped walking 
before the end of 6 min, e.g., due to fatigue, we accepted 
the walked distance as 6MWD. All 6MWT study data were 
collected by study personnel and stored in the study data-
base, the treating cardiologists were blinded to the study 
results. The distance covered was expressed as percentage 
of predicted (6MWD%) according to Geiger et al., account-
ing for height, gender, and age [6]. Calculation of 6MWD% 
was done after closure of the database and used for study 
purposes only.
As part of the follow-up study, in addition to the 6MWT, 
multiple data were recorded on the same patient visit: weight 
and height, current heart failure medication and dosage, New 
York Pediatric Heart Failure Index (NYPHFI), NT pro-BNP, 
and a standardized echocardiogram including left ventricular 
end-diastolic dimension (LVEDD) and fractional shortening 
(FS).
The study endpoint was death or heart transplantation 
(HTx). The decision to list a patient for HTx was made by a 
team of treating physicians based on commonly accepted cri-
teria [12]. The team was blinded to the results of the 6MWT. 
In addition, we recorded the status of the patients at the end 
of the study, after their last study visit: ongoing disease or 
recovered. Recovery was defined as 2 consecutive echocar-
diograms with normalized LVEDD and FS, the date of the 
first normalized echocardiogram was considered as date of 
recovery. Echocardiograms were analyzed and reviewed by 
study personnel who were blinded to the patient’s name, 
previous echocardiograms, and other study results.
Continuous variables with normal distribution are 
described as mean (standard deviation, SD), or as median 
(interquartile range, IQR) otherwise. Categorical variables 
are described as numbers and percentages. Differences in 
6MWT characteristics between patients with and without the 
study endpoint were compared by Student’s t tests (normal 
distribution) or Mann–Whitney tests.
We applied a linear mixed effects model (LMEM) for lon-
gitudinal data to study the temporal evolution of 6MWD%, 
while accounting for the correlation between measure-
ments in the individual patient. Subsequently, the LMEM 
was combined with a Cox proportional hazard regression 
model in a so-called joint model (JM) to explore the associa-
tion between 6MWD% (repeatedly measured) and the study 
endpoint. We included time since diagnosis as covariate in 
the JM.
We studied cumulative event-free survival of the study 
endpoint by the method of Kaplan–Meier. In a previous 
study, we showed that pediatric DCM patients with baseline 
6MWD% < 63% have high risk of death or heart transplant 
during prolonged follow-up [10]. Against this background, 
we separated our study cohort according to this threshold, 
and compared cumulative event-free survival by a log-rank 
test.
The level of statistical significance for all analyses was 
set at p = 0.05. Analyses were performed using IBM SPSS 
statistics 24 (IBM, New York, USA) and R statistical soft-
ware version 3.5.1 (package JMbayes).
Results
Eighty-five patients met the inclusion criteria, of which 57 
performed at least one 6MWT. Twenty-eight patients did not 
perform a 6MWT: 14 patients were too ill (e.g., admitted at 
the PICU) and reached an endpoint before a 6MWT could 
be obtained. Another 14 patients did not perform a 6MWT 
due to logistical reasons (Fig. 1). Nineteen of the 57 patients 
were included early after diagnosis, whereas 38 patients had 
been diagnosed before 2010 and were included relatively 
late after diagnosis. Patient characteristics are described in 
Table 1. At the first 6MWT, the median age was 11.1 years 
(IQR 7.3–14.5), median time since diagnosis was 3.6 years 
(IQR 0.5–7.1), and median time since study inclusion was 
0.1 years (IQR 0.0–0.9). Idiopathic DCM was diagnosed 
in 47%, and the majority of patients were treated with 
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ACE- inhibitors (90%) and β-blockers (78%). The median 
NYPHFI at the baseline 6MWT was 8 (IQR 4–11; Table 1). 
For 49 patients, we previously reported the results of a single 
6MWT and outcome [10].
Median observation time per patient was 3.0 years (IQR 
1.5–5.1), in patients with the study endpoint, median obser-
vation was 1.3 years (IQR 0.2–2.1), and in patients without 
the study endpoint, median observation was 3.8 years (IQR 
2.1–5.3; p = 0.001). In this time frame, 277 6MWTs were 
performed, and 47 of the 57 patients performed more than 
one 6MWT. The median number of 6MWTs per patient 
was 4 (IQR 2–6). The median number of 6MWTs per year 
follow-up was 2.7 (IQR 1.0–2.9). The mean distance walked, 
including all available tests, was 462 m (± 122), the mean 
6MWD% was 69% (± 17) (Table 1).
In the course of the study, 14 of the 57 patients in whom a 
6MWT was available, reached a study endpoint: 11 patients 
were transplanted at a median of 5.7 years after diagnosis 
(IQR 2.5–11.0) and 3 patients died, 1.3, 2.3, and 8.3 years 
after diagnosis. Death was caused by DCM-related ventricu-
lar arrhythmia in one patient, end-stage heart failure in a set-
ting of a contra-indication for HTx in the second patient, and 
multi-organ failure in a patient with an additional glycogen 
storage disease.
In patients who reached a study endpoint, median time 
from the last 6MWT to the study endpoint was 0.25 years 
(IQR 0.16–0.77). Median time since diagnosis to the first 
6MWT was 3.2 years (IQR 0.4–6.8), which was the same as 
in patients who did not reach a study endpoint. The median 
number of 6MWTs was the same in patients with and with-
out a study endpoint (Table 2). At the last follow-up visit, 
4 of the remaining 43 patients had recovered, whereas 39 
patients had ongoing disease. Three recovered children 
showed an increase in 6MWD%, the fourth performed only 
one test. The low number of recovered patients did not allow 
for statistical analysis.
At the first 6MWT, median 6MWD% was 68% (IQR 
53–82%). In patients with a study endpoint, 6MWD% was 
53% (IQR 33–61), compared to 74% (IQR 60–84) in patients 
without a study endpoint (p = 0.003) (Table 2). Transplant-
free survival was significantly higher in patients with a first 
6MWD% ≥ 63%. In children with a first 6MWD% ≥ 63%, 
1-year transplant-free survival was 96% (95% CI 89 to 100), 
2-year transplant-free survival was 92% (95% CI 81 to 100) 
in contrast to children with a first 6MWD% < 63% in whom 
1-year transplant-free survival was 74% (95% CI 56 to 92) 
and 2-year transplant-free survival was 64% (95% CI 44 
to 84) (log-rank test p = 0.002; Fig. 2). Thus, a 6MWD% 
lower than 63% was associated with an increased risk of 
heart transplantation or death (hazard ratio 10.8; 95% CI 
2.4 to 49).
At any time during follow-up, the average estimate of 
6MWD% was significantly lower in patients with a study 
endpoint compared to patients without a study endpoint 
(Fig. 3). Furthermore, we found no meaningful change in 
6MWD% over time both in patients with and without a study 
endpoint (Fig. 3). Notably, in patients who reached an end-
point, 6MWD% did not change over time and did not sud-
denly decrease prior to the endpoint. When we plotted the 
results of the 6MWD% against years since diagnosis, we 
N= 85 eligible paents
N=57 one ore more 
6MWT
N=14 too ill to 
perform 6MWT, eg 
admied on PICU
N=14 no 6MWT due 
to logiscal reasons
Fig. 1  Flow diagram of eligible patients and included patients
Table 1  Characteristics of the study cohort (n = 57) at the moment of 
baseline 6-min walk test
DCM dilated cardiomyopathy, 6MWT 6-min walk test, NYPHF New 
York University Pediatric Heart Failure Index, range 0–30, LVEDD 
Left ventricular end-diastolic dimension, SF shortening fraction
Time since diagnosis, years, median (IQR) 3.5 (0.5–7.1)
Time since study inclusion, years, median 
(IQR)
0.1 (0.1–0.9)
Gender, female, n (%) 68 (47%)
Age, years, median IQR 11.1 (IQR 7.3–14.5)
Cause of DCM (n, %)
 Idiopathic 26 (47)
 Genetic or familial 8 (14)
 Other 23 (40)
Heart failure score, NYPHFI median (IQR) 8 (4–11)
Medication, n (%)
 β-blockers 45 (78%)
 Ace inhibitors 51 (90%)
 Anti-coagulants 29 (51%)
 Diuretics 32 (56%)
Echocardiografic parameters, mean (SD)
 LVEDD z score 4.7 (2.9)
 SF 18.3 (6.7)
NT-pro BNP, pg/ml, median (IQR) 1873 (390–5021)
Endpoint
 Death/transplantation 14
 Ongoing disease 39
 Recovered 4
Number of 6MWT per patient, median (IQR) 4 (2–6)
6MWT, meters, mean (SD) 462 (122)
6MWD% of predicted, %, mean (SD) 69 (17)
Total follow-up time per patient, years, median 
(IQR)
3.0 (1.5–5.1)
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also found that they were constant over time (Fig. 4), indi-
cating that there was no systematic difference in the results 
obtained early and later after diagnosis. The variability of 
the 6MWD% within the individual patient was considerable 
(Fig. 5), suggesting that obtaining more than one 6MWT 
would be useful to obtain a reliable mean estimate of the 
patient. An absolute 1% lower 6MWD% was associated with 
a 11% higher risk (hazard) of the study endpoint (HR 0.90, 
Table 2  Repeated measurement of 6MWT, comparing patients with a study endpoint to patients without a study endpoint
Comparison of patients with SE vs patients without SE using Mann–Whitney test
All numbers are median and Inter Quartile Range (IQR)
SE study endpoint, Dx diagnosis
a Years
All patients (n = 57) SE (n = 14) No SE (n = 43) p value
Time Dx-fist  6MWTa 3.6 (0.5–7.1) 3.2 (0.4–6.8) 3.6 (0.5–7.4) 0.81
Time last 6MWD% to PEP or end of  studya 0.08 (0.0–0.46) 0.25 (0.16–0.77) 0.00 (0.00–0.38) 0.004
Total FU  timea 3.0 (1.3–5.1) 1.3 (0.2–2.1) 3.8 (2.1–5.3) 0.007
Number of 6MWT per patient 4 (2–6) 3 (1–6) 4 (2–7) 0.70
Number of 6MWT per year follow-up 2.7 (1.0–2.9) 3.7 (2.4–6.6) 1.6 (0.9–2.5) 0.004
Fig. 2  Transplant-free survival 
curves of DCM patients with 
6MWD ≤ 63% of predicted 
compared to patients with 
6MWD > 63% of predicted
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Fig. 3  Serial measurement of 6MWD expressed as percentage of pre-
dicted, time before study endpoint. The average estimates of the lon-
gitudinal trajectory of 6MWD%: the black line indicates the patients 
without a study endpoint, the red line the patients with a study end-
point. The dashed lines depict the 95% confidence interval
Fig. 4  Serial measurement of 6MWD expressed as percentage of pre-
dicted, time since diagnosis. The average estimates of the longitudinal 
trajectory of 6MWD%: the black line indicates the patients without a 
study endpoint, the red line the patients with a study endpoint. The 
dashed lines depict the 95% confidence interval
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95% CI 0.86–0.95 p < 0.001). In clinical practice this means 
that when comparing 2 patients at any given moment after 
diagnosis, the one with a 1% lower 6MDW% has an 11% 
increased risk of death or HTx.
Discussion
In this study, we confirm the usefulness of the 6MWT as a 
tool to identify children with DCM at a high risk of adverse 
outcome. In the studied time frame, 6MWD% was signifi-
cantly lower in patients who reached the study endpoint of 
death or HTx, compared to those who did not. The 6MWD% 
remained constant throughout 3 years of observation, both in 
patients who reached the study endpoint, and in those who 
did not. As 6MWD% tends to vary within the individual 
patient, at least two 6MWTs seem to be needed to obtain a 
reliable adequate indication of 6MWD%. Thereafter, repeat-
ing the 6MWT seems to have little added value.
In adult heart failure literature, data on the use of serial 
6MWT are scarce, but a number of studies have shown 
that repeating 6MWT is useful to evaluate effectiveness of 
therapeutic interventions. A short-term improvement in 6 
MWD after a drug intervention in hospitalized patients with 
chronic heart failure was a significant independent predictor 
of survival [2]. Likewise, in patients with moderate to severe 
heart failure, cardiac resynchronization therapy results in 
significant improvement in 6MWD and in survival [3]. In 
contrast, in the majority of trials that were reviewed, the 
6MWD did not increase after a pharmacological intervention 
in patients with chronic stable heart failure [13]. Combining 
both findings would indicate that repeating the 6MWT is 
helpful to evaluate the effect of a therapeutic intervention 
on survival in patients with moderate to severe heart failure.
Upfront, we expected that 6MWD% would decrease in 
the patients who reached an endpoint. Also, we hypothe-
sized that 6MWD% might increase in the combined group of 
patients who recover or have ongoing disease. However, our 
results did not confirm these expectations as 6MWD% was 
stable from early after diagnosis onward, both in children 
who reached an endpoint and those who did not. Moreo-
ver, it was significantly lower in those reaching an end-
point throughout the time of observation (Fig. 3). Notably, 
6MWTs were only obtained in patients who were relatively 
stable. In two potentially unstable phases of the disease, 
directly after diagnosis and shortly before death or HTx, 
a substantial number of patients did not perform a 6MWT. 
Sixteen percent of potentially eligible patients never per-
formed a 6MWT, because they were too ill and reached an 
endpoint before a 6MWT could be done. In that respect, not 
being able to perform a 6MWT can be considered an omi-
nous sign. On the other end of the spectrum, most patients 
who did perform one or more 6MWT and reached an end-
point within the study period did not perform a 6 MWT 
in the last phase of the disease: 8 of the 14 children with a 
study endpoint were listed for HTx after the last available 
6MWT, and were hospitalized awaiting transplantation.
There are several limitations to this study. Firstly, we 
could not obtain a 6MWT in a number of patients due to 
logistical difficulties that come with a multicenter study. 
However, the 14 patients we missed were not significantly 
different from the study cohort in terms of age, gender, 
cause of DCM, NYPHFI, and percentage of study end-
points (results not shown). We believe therefore that the 
study cohort was an unbiased selection and that missing 
6MWTs have not led to an important change in the results 
and conclusions of our study. Secondly, the studied cohort 
is relatively small, though compared to other pediatric stud-
ies using 6MWT to predict outcome comparable or larger 
in the number of children that we studied and the number 
of 6MWTs that were obtained. REFS Moreover, it is the 
first study on serial measurements of 6MWD% in children 
with DCM. Nevertheless, one could hypothesize that in a 
study with a larger cohort of children with DCM patients, 
we would have been able to demonstrate that 6MWD% 
significantly changes over time and that this change would 
identify patients with a higher risk of reaching an endpoint. 
The graph in Fig. 3, however, does not provide much support 
for that idea as it depicts that there is no change at all over 
time in 6MWD%, in both groups. We pose that expanding 
the study cohort would not lead to a fundamental change in 
the results we found. Thirdly, the great majority of study 
endpoints reached in this study was HTx, the number of 
deaths was low. This is in line with other studies reporting 
on outcomes in children with DCM, showing that in general, 
deaths occur relatively early after diagnosis and that HTx 
takes place later after diagnosis [14–16]. In this respect, it 
Fig. 5  Serial measurement of 6MWD expressed as percentage of pre-
dicted, time before study endpoint. The average estimates of the lon-
gitudinal trajectory of 6MWD%: the black line indicates the patients 
without a study endpoint, the red line the patients with a study end-
point. The dashed lines depict the 95% confidence interval. The indi-
vidual patients are plotted, the colored lines indicate the patients with 
the study endpoint
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is fair to state that 6MWTs identify the patients at a high 
risk for HTx rather than the patients at a high risk to die. 
Fourthly, a similar amount of 6MWTs were performed in 
children who did and did not reach a study endpoint, but the 
6MWT were performed in a shorter time frame. This reflects 
the clinical practice in which the most seriously affected 
children are seen more often at the outpatient clinic. Lastly, 
the patient cohort we studied contains a low number of chil-
dren that recover compared to our previous reports and large 
cohorts of children with DCM. The fact that children under 
6 years were not included in this study is probably an impor-
tant explanation as recovery in this age group is relatively 
common [14–17].
We conclude that, based on the current study, 6MWT 
is a useful tool to identify children with DCM at a high 
risk of death or heart transplantation. In children who are 
able to perform a 6MWT, 6MWD% remains constant over 
time, early after diagnosis and in the years thereafter, in 
those reaching an endpoint, 6MWD% is significantly lower 
throughout time, than in those not reaching an and endpoint. 
Initially, at least 2 6MWT are needed to reliably estimate 
6MWD%, thereafter repeating 6 MWT has little added 
value.
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